R&D Restructurings Aim To Placate Investors While Pharma Waits For Results
In response to poor R&D productivity and declining revenue as drug patents expire, Big Pharma companies have shrunk drastically to keep shareholders happy while they try to retool moribund R&D strategies.
More from Archive
More from Pink Sheet
Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.